Latest filing published 25 Aug 2025 for Ardelyx, INC., €36k.
Filing timeline
BuySaleInsider track record
Closed purchases
Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- +321.1%Entry US$1.09 · Close at T+365 US$4.59
- -71.5%Entry US$478.65 · Close at T+365 US$136.20
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Justin A. Renz: trading record in brief
This profile gathers the share dealings of Justin A. Renz across 3 companies, led by Ardelyx, Inc., Karyopharm Therapeutics Inc. and EPIRUS Biopharmaceuticals, Inc. We count 39 filings; the first trade dates from 10 February 2014 and the latest from 21 August 2025.
In open-market terms, that means 2 purchases worth €139k on one side and 27 sales worth €1.7M on the other. Taken together, the sales exceed the purchases by €1.5M. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The rest of the record consists of 8 share grants and 2 option exercises. So far in 2025, the count stands at no purchases and 3 sales.
On 25 August 2025 came the latest disclosure, an open-market sale for €36k in Ardelyx, Inc. The latest purchase dates back some time: it was published 1,530 days ago, on 1 September 2022. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Justin A. Renz
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 7,037 shares@ US$5.93179.4% of flowCommon StockSEC:0001628280-25-041137:0
- 7,218 shares@ US$4.08146.8% of flowCommon StockSEC:0001628280-25-027431:0
- 136,680 shares0Common StockSEC:0001628280-25-008798:0
- 5,171 shares@ US$5.6237.3% of flowCommon StockSEC:0001628280-25-007232:0
- 5,260 shares@ US$4.79456.2% of flowCommon StockSEC:0001628280-24-049053:0
- 5,289 shares@ US$5.86037.3% of flowCommon StockSEC:0001628280-24-038291:0
- 5,167 shares@ US$7.8119.7% of flowCommon StockSEC:0001628280-24-024944:0
- 5,341 shares@ US$8.746311.3% of flowCommon StockSEC:0001610717-24-000087:0
- 127,750 shares0Common StockSEC:0001628280-24-001684:0
- 225,000 shares@ US$6.356176.1% of flowCommon StockSEC:0001628280-23-042828:1
- 75,000 shares@ US$0.9917.6% of flowCommon StockSEC:0001628280-23-042828:0
- 2,873 shares@ US$4.36223.0% of flowCommon StockSEC:0001628280-23-039902:0
- 2,884 shares@ US$3.55182.4% of flowCommon StockSEC:0001628280-23-030404:0
- 2,873 shares@ US$3.65322.5% of flowCommon StockSEC:0001104659-23-064390:0
- 3,439 shares@ US$3.0012.5% of flowCommon StockSEC:0001567619-23-003769:0
- 78,000 shares0Common StockSEC:0001567619-23-000645:0
- 61 shares@ US$1.94150.0% of flowCommon StockSEC:0001567619-22-020846:0
- 1,443 shares@ US$1.94930.2% of flowCommon StockSEC:0001567619-22-020846:1
- 3,000 shares@ US$0.61880.5% of flowCommon StockSEC:0001567619-22-016958:0Canonical exit: 29 Nov 2022 (T+90)
- 6 shares@ US$0.98020.0% of flowCommon StockSEC:0001567619-22-016641:1
- 12 shares@ US$0.98010.0% of flowCommon StockSEC:0001567619-22-016641:2
- 1,480 shares@ US$0.98370.4% of flowCommon StockSEC:0001567619-22-016641:0
- 1,518 shares@ US$0.63560.1% of flowCommon StockSEC:0001567619-22-012557:1
- 71,794 shares@ US$0.650911.4% of flowCommon StockSEC:0001567619-22-012557:0
- 1,528 shares@ US$0.67140.3% of flowCommon StockSEC:0001567619-22-011524:0
25 of 39 declarations
